Fianlimab (REGN3767): A Comprehensive Clinical and Strategic Analysis of a Novel LAG-3 Inhibitor in Oncology

Executive Summary

Fianlimab (REGN3767) is an investigational, high-affinity, fully human monoclonal antibody that targets the Lymphocyte Activation Gene-3 (LAG-3) immune checkpoint. Developed by Regeneron Pharmaceuticals, fianlimab represents a significant advancement in the field of immuno-oncology and is being evaluated primarily in combination with the anti-PD-1 antibody cemiplimab (Libtayo®). This combination aims to provide a more potent and comprehensive reversal of T-cell exhaustion, a key mechanism of tumor immune evasion, than is achievable with anti-PD-1 monotherapy.

The core thesis of this report is that fianlimab, based on compelling early-phase clinical data, is positioned as a potential best-in-class LAG-3 inhibitor. Its extensive clinical development program is strategically engineered not only to secure market entry but to challenge and potentially displace existing standards of care. This includes the first-to-market LAG-3/PD-1 combination, Opdualag™ (relatlimab and nivolumab), through a high-reward strategy of demonstrating clinical superiority in direct, head-to-head pivotal trials.

Key clinical findings from the foundational Phase 1 study (NCT03005782) have been particularly encouraging, especially in advanced melanoma. The combination of fianlimab and cemiplimab has demonstrated objective response rates (ORR) consistently exceeding 60% in treatment-naïve patient populations, a figure that is approximately double the rate historically observed with anti-PD-1 monotherapy in similar settings.[1] Furthermore, long-term follow-up has revealed not only durable responses but also a significant deepening of these responses over time, with the complete response (CR) rate increasing from 12% to 25% at a median follow-up of 23 months.[3] This level of activity, coupled with a median progression-free survival (PFS) of 24 months in this population, suggests a profound and persistent anti-tumor effect.[3]

The safety profile of the fianlimab-cemiplimab combination has been characterized as generally acceptable and consistent with the known profile of anti-PD-1 monotherapy.[1] However, a distinct safety signal has emerged in the form of an elevated rate of adrenal insufficiency, occurring in approximately 12% of patients.[4] While manageable, this immune-related adverse event requires careful monitoring and represents a key point of differentiation from other checkpoint inhibitor regimens.

Regeneron's strategic outlook for fianlimab is ambitious. The clinical program is defined by pivotal Phase 3 trials designed to prove superiority against both the established PD-1 inhibitor standard-of-care, pembrolizumab, and the direct LAG-3 competitor, Opdualag.[6] Concurrently, the development of a fixed-dose combination (FDC) of fianlimab and cemiplimab is underway, a critical step for achieving commercial parity and convenience in a competitive market.[8] The success of this program hinges on the outcomes of these large-scale trials. Positive data readouts have the potential to redefine the treatment paradigm for advanced melanoma and establish fianlimab as a cornerstone of Regeneron's growing oncology franchise.

Scientific Foundation and Mechanism of Action

Fianlimab: A High-Affinity, Fully Human Anti-LAG-3 Monoclonal Antibody

Fianlimab, identified by the development code REGN3767 and synonyms including R3767 and WHO 11182, is a fully human monoclonal antibody designed to target the Lymphocyte Activation Gene-3 (LAG-3) protein.[5] It is classified pharmacologically as an immune checkpoint inhibitor, a LAG-3 antibody, and an antineoplastic agent with both inhibitory and modulatory actions.[5]

The antibody was invented and is being developed by Regeneron Pharmaceuticals, a leading biotechnology company headquartered in Tarrytown, New York.[13] Fianlimab was generated using Regeneron's proprietary VelocImmune® technology platform.[1] This platform employs genetically engineered mice with humanized immune systems, enabling the rapid creation of high-affinity, fully human antibodies that are less likely to provoke an immunogenic response in patients compared to chimeric or humanized antibodies derived from other species. This same advanced technology was utilized to develop cemiplimab (Libtayo®), the anti-PD-1 antibody that serves as the primary combination partner for fianlimab in its clinical development program.[1]

A critical aspect of fianlimab's molecular design is its structure as a hinge-stabilized immunoglobulin G4 (IgG4) monoclonal antibody.[15] The choice of the IgG4 isotype is a deliberate and significant feat of antibody engineering. The primary function of an immune checkpoint inhibitor like fianlimab is to block the interaction between its target receptor (LAG-3) and its ligand, thereby preventing the transmission of an inhibitory signal to the T-cell. It is not intended to eliminate the T-cell itself. Different antibody isotypes possess varying capacities to engage the body's immune effector functions, such as Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), which can lead to the destruction of the cell to which the antibody is bound. The IgG1 isotype, for example, is highly potent at inducing ADCC. If an IgG1 isotype were used for an anti-LAG-3 antibody, it could lead to the depletion of the very tumor-infiltrating lymphocytes the therapy aims to activate, a counterproductive outcome. In contrast, the IgG4 isotype has minimal effector function. By selecting the IgG4 backbone for both fianlimab and its partner cemiplimab, Regeneron has engineered these molecules to act as pure antagonists, effectively blocking their respective pathways without causing unintended destruction of the target T-cell population. The additional "hinge-stabilized" modification enhances the antibody's structural integrity, preventing a phenomenon known as fab-arm exchange and ensuring the molecule remains stable and functionally bivalent in vivo.

Attribute	Description	Source Snippets
Drug Name	Fianlimab	10
Synonyms	REGN3767, R3767, anti-LAG-3 MoAb REGN3767, WHO 11182	5
Developer	Regeneron Pharmaceuticals	12
Drug Class	Immune Checkpoint Inhibitor, LAG-3 Antibody, Antineoplastic	10
Target	Lymphocyte Activation Gene-3 (LAG-3; CD223)	5
Mechanism of Action	Binds to LAG-3 on T-cells, blocking its interaction with MHC class II and thereby restoring T-cell activation and anti-tumor immune response.	11
Partner Drug	Cemiplimab (Libtayo®), an anti-PD-1 monoclonal antibody.	5
Technology Platform	VelocImmune®	1

The LAG-3 Pathway: A Key Regulator of T-Cell Exhaustion

The molecular target of fianlimab is the LAG-3 protein, also known as CD223.[10] LAG-3 is a type I transmembrane protein belonging to the immunoglobulin superfamily (IgSF) and functions as a critical inhibitory immune checkpoint receptor.[11] In a healthy immune system, LAG-3 plays a role in maintaining immune homeostasis by downregulating T-cell responses to prevent excessive inflammation and autoimmunity.

However, in the context of cancer, this inhibitory function can be co-opted by tumors to facilitate immune evasion. LAG-3 is upregulated on various immune cells following chronic antigen stimulation, most notably on activated CD4+ and CD8+ T-cells, regulatory T-cells (Tregs), and natural killer (NK) cells.[21] Its expression on tumor-infiltrating lymphocytes (TILs) is a hallmark of a phenomenon known as T-cell exhaustion, a state of dysfunction where T-cells lose their capacity to proliferate and exert their cytotoxic, tumor-killing functions.[11]

LAG-3 exerts its inhibitory effects through interactions with several ligands, the canonical ligand being Major Histocompatibility Complex (MHC) class II molecules, which are often expressed on the surface of tumor cells and antigen-presenting cells within the tumor microenvironment.[11] The binding of LAG-3 on a T-cell to MHC class II on a tumor cell transmits a negative signal into the T-cell, suppressing its activation, proliferation, and cytokine production, thereby contributing to tumor-mediated immune suppression.[11]

Rationale for Dual Checkpoint Blockade: Synergistic Targeting of LAG-3 and PD-1

The mechanism of action of fianlimab is direct and specific. Upon intravenous administration, fianlimab circulates and binds with high affinity to the LAG-3 receptor expressed on TILs.[11] This binding physically obstructs the interaction between LAG-3 and its MHC class II ligand, effectively cutting the inhibitory signal that would otherwise suppress T-cell function.[11] By "releasing this brake," fianlimab is designed to restore the effector functions of exhausted T-cells, leading to the activation of antigen-specific T lymphocytes and an enhancement of cytotoxic T-lymphocyte (CTL)-mediated lysis of tumor cells, ultimately resulting in a reduction of tumor growth.[11]

The scientific rationale for combining fianlimab with an anti-PD-1 agent like cemiplimab is grounded in the biology of T-cell exhaustion. Preclinical studies have consistently shown that LAG-3 and another key checkpoint receptor, Programmed cell death-1 (PD-1), are frequently co-expressed on the same exhausted TILs within the tumor microenvironment.[16] This co-expression suggests that tumors often employ multiple, non-redundant inhibitory pathways to maintain a state of immune suppression. Consequently, blocking only the PD-1 pathway may be insufficient to fully reinvigorate an exhausted T-cell, as the LAG-3 pathway can remain active and continue to transmit inhibitory signals.

The central hypothesis is that the concurrent blockade of both LAG-3 and PD-1 can achieve a synergistic anti-tumor effect that is greater than the additive effects of inhibiting each pathway alone.[1] By blocking two distinct inhibitory mechanisms simultaneously, the combination of fianlimab and cemiplimab aims to more comprehensively reverse T-cell exhaustion and unleash a more potent and durable anti-tumor immune response.

This hypothesis was validated in preclinical models that provided the direct rationale for the clinical development program. In studies using humanized mice, in which the murine PD-1 and LAG-3 genes were replaced with their human counterparts, the combination of fianlimab and cemiplimab led to significantly enhanced anti-tumor activity and increased secretion of pro-inflammatory cytokines by tumor-specific T-cells compared to treatment with either antibody alone.[16] These compelling preclinical results provided a strong scientific foundation for advancing the combination into human clinical trials.

The Fianlimab Clinical Development Program

Overview of Clinical Strategy

The clinical development strategy for fianlimab is robust, ambitious, and centered on its combination with cemiplimab (Libtayo®), Regeneron's proprietary anti-PD-1 inhibitor.[1] This approach creates a proprietary dual-checkpoint blockade regimen, allowing Regeneron to maintain full control over its development and commercialization. This strategy is a clear demonstration of a company leveraging its foundational assets to build a comprehensive immuno-oncology portfolio. By exclusively pairing fianlimab with cemiplimab, Regeneron avoids partnerships and retains the full potential value of the combination. This positions the fianlimab/cemiplimab duo as a distinct therapeutic entity, designed to compete directly with other established checkpoint inhibitor combinations, rather than allowing fianlimab to be used with competitor PD-1 agents. This "fast-follower" approach, coming after the approval of the first LAG-3 combination, is differentiated by its proprietary nature and its aggressive goal of establishing a new, superior standard of care.

The program is investigating fianlimab across a broad spectrum of cancers, reflecting the wide applicability of checkpoint inhibition. This includes numerous solid tumors and hematological malignancies. The most advanced investigations are in malignant melanoma (Phase III), followed by non-small cell lung cancer (NSCLC) (Phase II/III), with earlier phase studies in colorectal cancer, solid tumors, and hematologic malignancies such as lymphoma.[5]

NCT Number	Trial Phase	Indication(s)	Intervention Arms	Primary Endpoint(s)	Status	Source Snippets
NCT03005782	Phase 1	Advanced Malignancies (Melanoma, NSCLC, HNSCC, ccRCC, etc.)	Fianlimab monotherapy; Fianlimab + Cemiplimab	DLTs, Safety, ORR (in expansion)	Active, not recruiting	5
NCT05352672	Phase 3	1L Unresectable/Metastatic Melanoma	Fianlimab (2 doses) + Cemiplimab vs. Pembrolizumab	PFS	Active, recruiting	6
NCT05608291	Phase 3	Adjuvant High-Risk Melanoma	Fianlimab (2 doses) + Cemiplimab vs. Pembrolizumab	RFS	Active, not recruiting	24
NCT06246916	Phase 3	1L Unresectable/Metastatic Melanoma	FDC Fianlimab + Cemiplimab vs. Relatlimab + Nivolumab (Opdualag™)	ORR	Active, recruiting	7
NCT05785767	Phase 2/3	1L Advanced NSCLC (PD-L1 ≥50%)	Fianlimab (2 doses) + Cemiplimab vs. Cemiplimab + Placebo	OS (Ph3), ORR (Ph2)	Active, recruiting	30
NCT05800015	Phase 2/3	1L Advanced NSCLC (any PD-L1)	Fianlimab (2 doses) + Cemiplimab + Chemo vs. Cemiplimab + Chemo + Placebo	OS (Ph3), ORR (Ph2)	Active, recruiting	33
NCT06190951	Phase 2	Peri-operative Resectable Melanoma	Fianlimab + Cemiplimab vs. Anti-PD1 alone	pCR, EFS	Active, recruiting	36

Foundational Phase 1 Study (NCT03005782) in Advanced Malignancies

The clinical journey of fianlimab began with the first-in-human NCT03005782 trial, a multi-part, open-label Phase 1 study initiated to evaluate the drug's safety, tolerability, and preliminary activity in patients with a range of advanced cancers.[5] The initial dose-escalation phase of the study was critical for establishing the foundational parameters for the entire development program.

The primary objectives of this initial phase were to assess the safety profile and determine the recommended Phase 2 dose (RP2D) for fianlimab, both as a monotherapy and in combination with a fixed dose of cemiplimab (350 mg Q3W).[5] Seventy-eight patients were enrolled in this part of the study, with 31 receiving fianlimab monotherapy and 47 receiving the combination.[5] The study explored various dose levels and schedules. Ultimately, no maximum tolerated dose (MTD) was reached, indicating a generally favorable tolerability profile across the doses tested.[5] A single dose-limiting toxicity (DLT), consisting of increased blood creatine phosphokinase and myasthenic syndrome, was reported in one patient receiving 3 mg/kg of fianlimab with cemiplimab.[5]

Pharmacokinetic (PK) analyses demonstrated that fianlimab exhibited dose-proportional exposure, and importantly, its PK profile was not altered by the co-administration of cemiplimab, nor did fianlimab affect the PK of cemiplimab.[5] This lack of drug-drug interaction is a favorable characteristic for a combination therapy. Based on the comprehensive safety, tolerability, and PK data, the selected dose for all subsequent Phase 2 and Phase 3 studies was established as 1600 mg of fianlimab administered intravenously every 3 weeks, in combination with 350 mg of cemiplimab Q3W.[5] This fixed dose is equivalent to approximately 20 mg/kg for an 80-kg individual.[5]

Following the successful completion of the dose-escalation phase, the study transitioned into a multi-cohort expansion phase. This phase enrolled patients with specific types of cancer into dedicated cohorts to gather more robust safety data and to assess the preliminary anti-tumor activity of the fianlimab-cemiplimab combination at the RP2D. It was the data from the expansion cohorts in advanced melanoma that proved to be particularly compelling, providing the strong signal of efficacy that justified the rapid and broad advancement of the fianlimab program into pivotal Phase 3 trials.[15]

Clinical Efficacy and Safety in Advanced Melanoma

The most mature and compelling clinical data for the fianlimab-cemiplimab combination comes from the expansion cohorts of the Phase 1 trial (NCT03005782) focused on patients with advanced melanoma. The results from these cohorts have consistently demonstrated high levels of clinical activity, particularly in patients who have not received prior checkpoint inhibitor therapy for advanced disease.

Efficacy in Treatment-Naïve Patient Populations (NCT03005782)

The primary evidence for fianlimab's efficacy is derived from two independent expansion cohorts of patients with advanced melanoma who were naïve to prior anti-PD-(L)1 therapy: an initial cohort (Cohort 6, n=40) and a subsequent confirmatory cohort (Cohort 15, n=40).[15] The consistency of results across these two separate cohorts has been a key factor in building confidence in the combination's potential.

The objective response rate (ORR) has been the standout efficacy metric. Initial reports from these cohorts showed remarkably high and reproducible ORRs, ranging from 62.5% to 65%.[2] A later combined analysis incorporating 98 patients (including a third cohort of patients with prior adjuvant therapy) reported an overall ORR of 61.2%.[15] Perhaps most impressively, longer-term follow-up data presented at major oncology conferences has shown not only the persistence of these responses but also their deepening over time. At a median follow-up of 23 months, a blinded independent central review (BICR) confirmed an ORR of 57% across the 98 patients. Within this, the rate of complete response (CR)—the disappearance of all signs of cancer—had more than doubled, increasing from 12% at an earlier time point to 25%.[3] This maturation of partial responses into complete responses over time is a strong indicator of a potent and durable anti-tumor effect.

This high response rate has translated into impressive durability and survival outcomes. While early analyses with a median follow-up of 12.6 months reported a median progression-free survival (mPFS) of 13.3 months, the longer-term follow-up at 23 months demonstrated a substantial extension of mPFS to 24 months.[3] In nearly all reported analyses, the median duration of response (mDOR) has not been reached, signifying that the majority of responding patients continue to experience clinical benefit without disease progression.[22]

Patient Cohort	N	Median Follow-up (months)	ORR (%, 95% CI)	CR Rate (%)	Median PFS (months, 95% CI)	Median DOR (months, 95% CI)	Source Snippets
Anti-PD-1-Naïve (Combined Cohorts 6, 15, 16)	98	12.6	61.2%	12%	13.3 (7.5 - NE)	Not Reached	3
Anti-PD-1-Naïve (Combined Cohorts 6, 15, 16)	98	23.0	57% (BICR)	25%	24.0 (12 - NE)	Not Reached	3
Post-Adjuvant PD-1 (Cohort 16)	18	9.7	56%	-	12.0 (1.4 - NE)*	Not Reached	15
PD-1 Refractory (Advanced Disease)	15	-	13.3%	7%	1.5 (1.3 - 7.7)	-	15
High-Risk (Elevated LDH)	32	12.6	53.1%	-	11.8 (3.7 - NE)	Not Reached (7.4 - NE)	22
High-Risk (Liver Mets)	21	12.6	42.9%	-	4.2 (1.2 - NE)	9.0 (2.8 - NE)	22
*PFS data for Post-Adjuvant cohort is from a subset of n=13 patients. NE = Not Estimated.

Efficacy in Patients with Prior PD-1 Exposure (NCT03005782)

The efficacy of the fianlimab-cemiplimab combination in patients with prior exposure to checkpoint inhibitors is nuanced and highly dependent on the clinical context of that prior exposure. In patients who had received anti-PD-1 therapy in the adjuvant (post-surgical) or neoadjuvant (pre-surgical) setting and subsequently relapsed (Cohort 16, n=18), the combination demonstrated substantial and clinically meaningful activity. Initial reports highlighted an impressive ORR of 56% to 61.5% in this population, with a median PFS of 12 months.[15] This was a significant finding, as it provided the first strong evidence that dual LAG-3/PD-1 blockade could overcome the resistance mechanisms that led to relapse after adjuvant PD-1 monotherapy, a setting of high unmet clinical need.[39]

However, the interpretation of this efficacy has been complicated by subsequent data updates. At a later medical meeting, the ORR for this cohort was revised downward to 39% (7 of 18 patients).[8] Regeneron publicly attributed this significant change to a "clerical error" and to the inherent difficulties in applying standardized RECIST 1.1 response criteria to assess disease in lymph nodes, which can be challenging to measure accurately.[8] While the revised 39% ORR still represents a clinically meaningful signal, the discrepancy has introduced a degree of uncertainty. This highlights the volatility of data from small, early-phase cohorts and underscores the critical importance of the ongoing, large-scale randomized trials to definitively establish the true magnitude of benefit in this specific patient population.

In stark contrast, the combination showed very limited efficacy in patients with truly PD-1 refractory disease—that is, patients who had progressed while receiving anti-PD-1 therapy for advanced or metastatic melanoma. In this heavily pretreated population (n=15), the ORR was only 13.3%, and the median PFS was a brief 1.5 months.[15] This result suggests that the mechanisms of acquired resistance to PD-1 blockade in the metastatic setting may be distinct and not readily overcome by the addition of LAG-3 inhibition alone.

Performance in High-Risk Subgroups and Biomarker Analyses

A key question for any new cancer therapy is its efficacy in patients with poor prognostic features. The fianlimab-cemiplimab combination has demonstrated robust activity in these high-risk subgroups. In an analysis of patients with elevated baseline lactate dehydrogenase (LDH), a well-established marker of poor prognosis in melanoma, the ORR was 53.1% and the mPFS was 11.8 months.[22] Similarly, in patients with liver metastases, another indicator of aggressive disease, the combination achieved an ORR of 42.9%.[22] These results compare favorably to historical outcomes for checkpoint inhibitors in these challenging populations.

Furthermore, the clinical benefit of the combination appears to be largely independent of the baseline expression levels of PD-L1 and LAG-3 in the tumor. In a post-hoc analysis, the ORR was 50% in patients with PD-L1 expression of less than 1% and 71% in those with PD-L1 expression of 1% or greater. A similar pattern was observed for LAG-3 expression, with an ORR of 50% in patients with LAG-3 expression below 1% and 61% in those with 1% or greater expression.[41] This suggests that fianlimab plus cemiplimab may provide broad clinical benefit without the need for patient selection based on these specific biomarkers, simplifying its potential clinical application.[42]

Pivotal Phase 3 Trials in Melanoma

Building on the strength of the Phase 1 data, Regeneron has launched a comprehensive and aggressive Phase 3 program in melanoma, designed to establish the fianlimab-cemiplimab combination as a new standard of care across multiple treatment settings.

• First-Line Metastatic Setting (NCT05352672): This is a cornerstone trial of the program. It is a large, randomized, double-blind study expected to enroll approximately 1,590 patients with previously untreated, unresectable or metastatic melanoma.[6] The trial is designed to demonstrate the superiority of the fianlimab-cemiplimab combination over the current standard of care for many patients, pembrolizumab (an anti-PD-1) monotherapy. The primary endpoint is PFS, with key secondary endpoints including overall survival (OS) and ORR.[3]
• Adjuvant Setting (NCT05608291): This large Phase 3 trial is evaluating the combination as a post-surgical treatment for patients with completely resected, high-risk melanoma (Stage IIB/C, III, or IV).[24] Approximately 1,564 patients will be randomized to receive either the fianlimab-cemiplimab combination or pembrolizumab monotherapy for one year. The primary endpoint is Recurrence-Free Survival (RFS), with the goal of showing that the dual blockade can more effectively prevent or delay disease recurrence than PD-1 inhibition alone.[25]
• Peri-operative Setting (NCT06190951): This Phase 2 trial is exploring the combination in the peri-operative setting for patients with resectable Stage III and IV melanoma.[36] Patients receive the immunotherapy combination both before (neoadjuvant) and after (adjuvant) surgery, a strategy aimed at maximizing the immune response to shrink tumors pre-operatively and eliminate residual microscopic disease post-operatively.[38]

Comprehensive Safety and Tolerability Profile in Melanoma

The overall safety profile of the fianlimab and cemiplimab combination is considered acceptable and is largely consistent with the well-characterized safety profile of anti-PD-1 monotherapy.[1] The types of immune-related adverse events (irAEs) observed are similar to those seen with agents like cemiplimab or pembrolizumab.

Across the combined melanoma cohorts from the Phase 1 trial (n=98), Grade 3 or higher treatment-emergent adverse events (TEAEs) were reported in 44% to 47% of patients.[3] Treatment-related adverse events (TRAEs) of Grade 3 or higher, those considered by the investigator to be related to the study drugs, occurred in a lower proportion of patients, approximately 22%.[15]

The most significant and distinguishing feature of the combination's safety profile is a notably higher incidence of adrenal insufficiency (AI) compared to what is typically seen with anti-PD-1 monotherapy. The rate of any-grade, treatment-related AI was reported to be between 11% and 12%, with approximately 5% of cases being Grade 3 or higher.[1] This rate is more akin to that observed with the highly potent but more toxic combination of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1).[39] While AI is a manageable condition with hormone replacement therapy, its increased frequency with the fianlimab-cemiplimab combination necessitates heightened clinical awareness and proactive monitoring for symptoms such as fatigue, nausea, and hypotension.

Other common AEs of any grade reported in the melanoma trials include dermatologic toxicities like rash (20%) and pruritus (16%), as well as systemic symptoms like fatigue, diarrhea (15%), and endocrine-related events such as hypothyroidism (12%).[1]

Adverse Event Category	Any Grade (%)	Grade ≥3 (%)	Key Details/Context	Source Snippets
All Treatment-Emergent AEs (TEAEs)	90-95%	44-47%	Overall incidence of any adverse event during treatment.	4
All Treatment-Related AEs (TRAEs)	60%	22%	AEs assessed by the investigator as related to the study drug.	15
Serious AEs	30-36%	-	Adverse events requiring hospitalization or deemed medically significant.	1
AEs Leading to Discontinuation	8-16%	-	Rate at which patients stopped treatment due to toxicity.	45
Adrenal Insufficiency	11-12%	5%	The most notable safety signal; higher than anti-PD-1 monotherapy.	1
Rash	20-27%	<1%	Common dermatologic toxicity associated with checkpoint inhibitors.	1
Pruritus (Itching)	16%	<1%	Another common dermatologic side effect.	1
Fatigue	13-31%	<1%	A very common, non-specific side effect of immunotherapy.	45
Diarrhea / Colitis	13-15%	7%	Important immune-related gastrointestinal toxicity.	1
Hypothyroidism	12-33%	<1%	Common endocrine toxicity requiring hormone replacement.	1

Expansion into Other Malignancies

While melanoma serves as the lead indication for fianlimab, Regeneron is pursuing a broad development strategy, investigating the combination with cemiplimab in a variety of other cancers where checkpoint inhibition is an established or emerging treatment modality.

Non-Small Cell Lung Cancer (NSCLC)

NSCLC represents a major area of focus for the fianlimab program, with multiple large-scale, late-stage trials underway. The strategy is to evaluate the addition of fianlimab to the standard anti-PD-1 backbone (cemiplimab), both as a monotherapy combination and with chemotherapy, targeting distinct patient populations based on PD-L1 expression.

• NCT05785767: This is a pivotal Phase 2/3 study in the first-line treatment of advanced NSCLC for patients whose tumors have high PD-L1 expression (≥50%).[30] In this setting, anti-PD-1 monotherapy is a standard of care. The trial is designed to determine if the dual blockade of fianlimab plus cemiplimab can produce superior outcomes, particularly in overall survival (the primary endpoint of the Phase 3 portion), compared to cemiplimab alone.[30]
• NCT05800015: This Phase 2/3 trial targets a broader first-line advanced NSCLC population, enrolling patients irrespective of their tumor PD-L1 expression levels.[33] The study compares a triplet regimen of fianlimab, cemiplimab, and platinum-based chemotherapy against the standard-of-care doublet of cemiplimab plus chemotherapy. The primary endpoint is again overall survival, aiming to show that adding LAG-3 blockade to the PD-1/chemotherapy backbone improves efficacy.[34]
• NCT06161441: Moving into earlier-stage disease, this Phase 2 trial is evaluating the fianlimab-cemiplimab-chemotherapy triplet in the peri-operative setting for patients with resectable Stage II-IIIB NSCLC.[49] The goal is to improve pathological response rates and long-term outcomes for patients undergoing surgery with curative intent.

Other Investigated Solid Tumors

The fianlimab program extends beyond melanoma and lung cancer, with early-phase data emerging in several other solid tumors.

• Head and Neck Squamous Cell Carcinoma (HNSCC): An expansion cohort of the Phase 1 trial (NCT03005782) provided an early signal of efficacy in HNSCC. Among 15 anti-PD-1-naïve patients, the combination achieved an ORR of 33%, with some responses proving to be highly durable. As expected, the response rate was lower (7%) in 15 patients who had prior experience with anti-PD-1 therapy.[48] These encouraging results in the naïve population have prompted the initiation of a dedicated randomized Phase 2 study (NCT06769698) to further evaluate the combination versus cemiplimab monotherapy in patients with PD-L1-positive recurrent or metastatic HNSCC.[50]
• Clear Cell Renal Cell Carcinoma (ccRCC): In a Phase 1 expansion cohort of heavily pretreated patients with advanced ccRCC, the combination demonstrated durable responses.[46] In patients who had received a prior VEGF tyrosine kinase inhibitor (TKI) but were naïve to PD-1 inhibitors, the ORR was 20%. In the more challenging population of patients who had been exposed to both a VEGF TKI and a PD-1 inhibitor, the ORR was 7%.[46] These data support the further development of the combination in metastatic ccRCC.
• Other Cancers: The clinical development program is actively exploring fianlimab in several other malignancies, with trials underway or planned in colorectal cancer, breast cancer, and multiple myeloma, as well as in the neoadjuvant setting for locally advanced kidney cancer.[13]

Competitive Landscape and Market Positioning

The therapeutic landscape for LAG-3 inhibitors is rapidly evolving, with fianlimab entering a market where a first-mover competitor has already established a clinical and commercial foothold. Regeneron's strategy appears to be predicated on demonstrating that fianlimab is not merely another option, but a clinically superior one.

The First-to-Market Competitor: Relatlimab + Nivolumab (Opdualag)

The primary competitor for fianlimab is the combination of relatlimab (an anti-LAG-3 antibody) and nivolumab (an anti-PD-1 antibody), which is developed and marketed by Bristol Myers Squibb under the trade name Opdualag™.[8] Opdualag received approval from the U.S. Food and Drug Administration (FDA) in March 2022, making it the first-in-class and, to date, the only approved LAG-3-based immunotherapy.[52]

The approval of Opdualag was based on the results of the pivotal Phase 2/3 RELATIVITY-047 trial.[52] In this study, the fixed-dose combination of relatlimab and nivolumab demonstrated a statistically significant improvement in progression-free survival compared to nivolumab monotherapy in patients with previously untreated advanced melanoma. The median PFS for the combination was 10.1 months, more than double the 4.6 months observed in the nivolumab-alone arm.[52] The ORR for Opdualag in this trial was 43.1%.[52] These efficacy benchmarks from the RELATIVITY-047 trial represent the primary data against which fianlimab's clinical performance will be judged by clinicians, regulators, and payers.

Head-to-Head Confrontation: The Harmony Trial (NCT06246916)

In a bold and confident strategic move, Regeneron has initiated a direct, head-to-head Phase 3 clinical trial to compare its fianlimab-cemiplimab combination directly against Opdualag.[7] This study, known as the Harmony Head-to-Head trial (NCT06246916), is a randomized, open-label study that will enroll approximately 560 patients with unresectable or metastatic melanoma.[7]

The design of this trial reveals much about Regeneron's competitive strategy. While the RELATIVITY-047 trial used PFS as its primary endpoint, Regeneron has selected ORR, as assessed by BICR, as the primary endpoint for the Harmony trial.[7] This is a calculated decision. The fianlimab combination's most striking feature in the Phase 1 data was its exceptionally high ORR of over 60%, a figure numerically superior to Opdualag's 43%. By choosing ORR as the primary endpoint, Regeneron is positioning the trial to play to its drug's apparent strength: the ability to induce deep and frequent tumor responses. A statistically significant superiority in ORR would provide a powerful and easily communicable marketing message to clinicians, suggesting a more potent anti-tumor effect, even if the eventual difference in PFS is more modest. A positive outcome in this trial would be a major commercial victory, providing clear evidence to support the argument for fianlimab's superiority over the established competitor.

Metric	Fianlimab + Cemiplimab (Phase 1, NCT03005782)	Relatlimab + Nivolumab (Phase 3, RELATIVITY-047)	Historical Anti-PD-1 Monotherapy (Benchmark)
Pivotal Trial	Phase 1 Expansion Cohorts	Phase 3 Randomized Controlled Trial	Various Phase 3 Trials (e.g., Keynote-006)
ORR (%)	61.2%	43.1%	~30-40%
CR Rate (%)	12% (increasing to 25% with follow-up)	16.3%	~5-10%
Median PFS (months)	13.3 (increasing to 24 with follow-up)	10.1	~6-8
Source Snippets	3	52	1

Note: Cross-trial comparisons should be interpreted with caution due to differences in study design, patient populations, and follow-up duration. This table is for illustrative purposes to contextualize the available data.

The Strategic Imperative of a Fixed-Dose Combination (FDC)

A critical factor in the commercial landscape for combination immunotherapies is the convenience of administration. Opdualag is marketed as a single-infusion, fixed-dose combination, simplifying pharmacy preparation and patient administration.[8] To achieve competitive parity and ensure ease of use in clinical practice, Regeneron recognized the necessity of developing its own FDC of fianlimab and cemiplimab.

The head-to-head trial against Opdualag (NCT06246916) is specifically designed to test this FDC formulation.[8] While initial regulatory submissions for fianlimab may be based on data from trials using separate infusions of the two antibodies, the Harmony trial is intended to generate the pivotal data required to support the approval and launch of an FDC. The successful development of an FDC is considered essential for the long-term commercial viability and market penetration of the fianlimab-cemiplimab regimen. The estimated primary completion date for this crucial trial is in 2027.[8]

Regulatory Status and Forward Outlook

Global Regulatory Status

As of the latest available information, fianlimab remains an investigational agent. It has not received marketing approval from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other major regulatory body worldwide for any indication.[1] Its use is currently restricted to clinical trials.

In terms of special regulatory designations designed to expedite development, Regeneron has announced that the combination of fianlimab plus Libtayo received Fast Track Designation from the FDA for the treatment of advanced melanoma.[64] This designation facilitates more frequent communication with the FDA and allows for a rolling review of the marketing application. However, there is no evidence in the available documentation to suggest that the combination has received the more significant Breakthrough Therapy Designation, which requires preliminary clinical evidence of substantial improvement over available therapies.[65]

Critical Milestones and Unanswered Questions

The future of the fianlimab program rests on the outcomes of its extensive and ambitious Phase 3 program. The most immediate and critical milestone is the data readout from the pivotal NCT05352672 trial, which compares the fianlimab-cemiplimab combination against pembrolizumab monotherapy in first-line advanced melanoma. Results from this trial were initially anticipated in the second half of 2024 but may now be expected in 2025, and they will form the basis for the first regulatory submissions for marketing approval.[8]

The primary challenge for Regeneron is to successfully translate the exceptionally promising efficacy signals observed in the relatively small Phase 1 expansion cohorts into statistically significant and clinically meaningful superiority in large, randomized Phase 3 settings. The program must also successfully navigate the clinical and regulatory scrutiny that may arise from the revised ORR data in the post-adjuvant melanoma cohort. Furthermore, a clear characterization of the adrenal insufficiency safety signal, along with robust guidelines for its monitoring and management, will be essential for physician confidence and patient safety.

Concluding Assessment

Fianlimab, when combined with cemiplimab, has emerged as a highly promising next-generation immunotherapy. The combination has demonstrated a compelling and potentially best-in-class efficacy profile in early-phase studies for advanced melanoma, characterized by high objective response rates, durable clinical benefit, and a remarkable deepening of complete responses over time.

Regeneron has crafted an aggressive and well-defined clinical and commercial strategy aimed at establishing superiority over both the current anti-PD-1 standard of care and the first-to-market LAG-3 competitor. The commitment to direct, head-to-head pivotal trials underscores the company's confidence in the fianlimab combination's potential.

The ultimate role of fianlimab in the oncology treatment armamentarium will be determined by the results of its extensive Phase 3 program. If the impressive early-phase efficacy is validated in these larger trials, the fianlimab-cemiplimab combination has the potential to establish a new standard of care in advanced melanoma and become a cornerstone of Regeneron's expanding oncology franchise. Conversely, a failure to demonstrate clear superiority in these definitive studies could relegate it to a secondary role in an increasingly competitive and crowded immunotherapy market. The upcoming data readouts are therefore highly anticipated and will be pivotal in shaping the future of LAG-3 inhibition in cancer therapy.

Works cited

1. Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations, accessed August 29, 2025, https://investor.regeneron.com/news-releases/news-release-details/fianlimab-lag-3-inhibitor-combined-libtayor-cemiplimab-shows/
2. Fianlimab (LAG-3 Inhibitor) Combined with Libtayo® (cemiplimab) Demonstrates Greater than 60% Response Rates in Two Independent Cohorts of Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors | Regeneron Pharmaceuticals Inc., accessed August 29, 2025, https://investor.regeneron.com/news-releases/news-release-details/fianlimab-lag-3-inhibitor-combined-libtayor-cemiplimab/
3. 'Cooking with gas': Regeneron sees its Opdualag rival as next big thing for treating solid tumors - Fierce Biotech, accessed August 29, 2025, https://www.fiercebiotech.com/biotech/cooking-gas-regenerons-opdualag-rival-companys-next-big-thing-solid-tumor-treatments
4. Regeneron to Highlight Progress Across Its Differentiated Oncology ..., accessed August 29, 2025, https://investor.regeneron.com/news-releases/news-release-details/regeneron-highlight-progress-across-its-differentiated-oncology
5. Fianlimab - Drug Targets, Indications, Patents - Patsnap Synapse, accessed August 29, 2025, https://synapse.patsnap.com/drug/8a983d591b554e96b1cf5fdeba566d72
6. A phase 3 trial of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma. - ASCO, accessed August 29, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT410890
7. A phase 3 trial of fixed dose combinations of fianlimab (anti–LAG-3) + cemiplimab (anti–PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma. | Journal of Clinical Oncology - ASCO Publications, accessed August 29, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.TPS9611
8. ESMO 2024 – Regeneron's fianlimab do-over | ApexOnco - Oncology Pipeline, accessed August 29, 2025, https://www.oncologypipeline.com/apexonco/esmo-2024-regenerons-fianlimab-do-over
9. Regeneron works to secure fianlimab | ApexOnco - Clinical Trials news and analysis, accessed August 29, 2025, https://www.oncologypipeline.com/apexonco/regeneron-works-secure-fianlimab
10. Fianlimab : Drug Detail - Cancer Knowledgebase (CKB), accessed August 29, 2025, https://ckb-core.genomenon.com/drug/show/8764
11. Definition of fianlimab - NCI Drug Dictionary - NCI, accessed August 29, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fianlimab
12. Fianlimab - Regeneron Pharmaceuticals - AdisInsight, accessed August 29, 2025, https://adisinsight.springer.com/drugs/800048609
13. Fianlimab by Regeneron Pharmaceuticals for Lymphoma: Likelihood of Approval, accessed August 29, 2025, https://www.pharmaceutical-technology.com/data-insights/fianlimab-regeneron-pharmaceuticals-lymphoma-likelihood-of-approval/
14. Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplimab) in Multiple Solid Tumor Types, accessed August 29, 2025, https://investor.regeneron.com/news-releases/news-release-details/regeneron-esmo-io-presentations-highlight-potential-fianlimab/
15. Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma - PubMed, accessed August 29, 2025, https://pubmed.ncbi.nlm.nih.gov/38900987/
16. First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies - AACR Journals, accessed August 29, 2025, https://aacrjournals.org/clincancerres/article/30/24/5601/750435/First-in-Human-Dose-Escalation-Study-of-Fianlimab
17. Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma | Journal of Clinical Oncology - ASCO Publications, accessed August 29, 2025, https://ascopubs.org/doi/10.1200/JCO.23.02172
18. www.cancer.gov, accessed August 29, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fianlimab#:~:text=Upon%20administration%2C%20fianlimab%20binds%20to,(MHC)%20class%20II%20molecules.
19. First-In-Human Dose-Escalation Study of Fianlimab, an Anti–Lymphocyte Activation Gene-3 Antibody, with Cemiplimab in patients - AACR Journals, accessed August 29, 2025, https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-23-3883/3508409/ccr-23-3883.pdf
20. First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies - PMC - PubMed Central, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11647203/
21. LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy - MDPI, accessed August 29, 2025, https://www.mdpi.com/2227-9059/11/7/1878
22. A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced melanoma: Poor-prognosis subgroup analysis. - ASCO, accessed August 29, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT409630
23. Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma - NCI, accessed August 29, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-04398
24. A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | UVA Health, accessed August 29, 2025, https://uvahealth.com/clinicaltrials/phase-3-trial-fianlimab-anti-lag-3-cemiplimab-versus-pembrolizumab-adjuvant-setting
25. A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | Dana-Farber Cancer Institute, accessed August 29, 2025, https://www.dana-farber.org/clinical-trials/23-092
26. A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | ClinicalTrials.gov, accessed August 29, 2025, https://clinicaltrials.gov/study/NCT05608291
27. A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | ClinicalTrials.gov, accessed August 29, 2025, https://clinicaltrials.gov/study/NCT06246916
28. R3767-ONC-22122: A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatilimab and Nivolumab in Participants with Unresectable or Metastatic Melanoma > Clinical Trials > Yale Medicine, accessed August 29, 2025, https://www.yalemedicine.org/clinical-trials/a-study-with-combinations-of-anti-lag-3-and-anti-pd-1-antibodies-in-adult-participants-with-advanced
29. Study Details | A Study With Combinations of Anti-LAG-3 and Anti ..., accessed August 29, 2025, https://clinicaltrials.gov/study/NCT06246916?intr=fianlimab&rank=7
30. A randomized, double-blind phase 2/3 study of Fianlimab (anti-lag-3 ..., accessed August 29, 2025, https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2024-0327.html
31. A phase 2/3 study of fianlimab plus cemiplimab versus cemiplimab in patients with advanced non-small cell lung cancer with tumors expressing PD-L1 ≥50%. - ASCO Publications, accessed August 29, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.TPS8663
32. A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | ClinicalTrials.gov, accessed August 29, 2025, https://clinicaltrials.gov/study/NCT05785767
33. A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer - Clinical Trials | Regeneron Pharmaceuticals, accessed August 29, 2025, https://clinicaltrials.regeneron.com/clinical-trials/a0MPr0000005iUAMAY/nct05800015
34. A phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy versus cemiplimab plus chemotherapy in first-line treatment of advanced non-small cell lung cancer. - ASCO Publications, accessed August 29, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.TPS8660
35. A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer | ClinicalTrials.gov, accessed August 29, 2025, https://clinicaltrials.gov/study/NCT05800015
36. Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma - UCSF Clinical Trials, accessed August 29, 2025, https://clinicaltrials.ucsf.edu/trial/NCT06190951
37. A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab Compared with Pembrolizumab in Patients with Resectable Stage III and IV Melanoma | UVA Health, accessed August 29, 2025, https://uvahealth.com/clinicaltrials/phase-2-peri-operative-trial-fianlimab-cemiplimab-compared-pembrolizumab-patients
38. A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma | ClinicalTrials.gov, accessed August 29, 2025, https://clinicaltrials.gov/study/NCT06190951
39. Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis. - ASCO, accessed August 29, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT418234
40. Fianlimab Combined With Cemiplimab Elicits Durable Responses in Advanced Melanoma, accessed August 29, 2025, https://www.targetedonc.com/view/fianlimab-combined-with-cemiplimab-elicits-durable-responses-in-advanced-melanoma
41. Fianlimab/Cemiplimab Demonstrates Persistent Activity in Advanced ..., accessed August 29, 2025, https://www.onclive.com/view/fianlimab-cemiplimab-demonstrates-persistent-activity-in-advanced-melanoma-independent-of-lag-3-and-pd-l1-status
42. Assessing LAG-3 & PD-1 inhibition with fianlimab & cemiplimab in advanced melanoma, accessed August 29, 2025, https://www.youtube.com/watch?v=_iDn-PSfu24
43. A phase 3 trial comparing fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) to pembrolizumab in patients with completely resected high-risk melanoma. - ASCO, accessed August 29, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT407128
44. Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination, accessed August 29, 2025, https://investor.regeneron.com/news-releases/news-release-details/regeneron-highlight-advances-asco-phase-3-adjuvant-libtayor/
45. Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma. | Request PDF - ResearchGate, accessed August 29, 2025, https://www.researchgate.net/publication/352071181_Clinical_activity_of_fianlimab_REGN3767_a_human_anti-LAG-3_monoclonal_antibody_combined_with_cemiplimab_anti-PD-1_in_patients_pts_with_advanced_melanoma
46. Fianlimab Plus Cemiplimab Yields Early Efficacy Signs in Pretreated Advanced ccRCC, accessed August 29, 2025, https://www.onclive.com/view/fianlimab-plus-cemiplimab-yields-early-efficacy-signs-in-pretreated-advanced-ccrcc
47. Fianlimab (LAG-3 Inhibitor) Combined with Libtayo® (cemiplimab) Demonstrates Greater than 60% Response Rates in Two Independent Cohorts of Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors - PR Newswire, accessed August 29, 2025, https://www.prnewswire.com/news-releases/fianlimab-lag-3-inhibitor-combined-with-libtayo-cemiplimab-demonstrates-greater-than-60-response-rates-in-two-independent-cohorts-of-patients-with-advanced-melanoma-naive-to-pd-1-or-pd-l1-inhibitors-301621636.html
48. A phase 1 study of fianlimab (anti–LAG-3) in combination with cemiplimab (anti–PD-1) in patients with advanced HNSCC. | Journal of Clinical Oncology - ASCO Publications, accessed August 29, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.6038
49. A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery | ClinicalTrials.gov, accessed August 29, 2025, https://clinicaltrials.gov/study/NCT06161441
50. A phase 2 study of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus cemiplimab plus placebo in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) with positive PD-L1 expression. - ASCO Publications, accessed August 29, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS6112
51. Clinical Trials Using Fianlimab - NCI, accessed August 29, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/fianlimab?pn=1
52. The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma - PMC, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10164023/
53. LAG 3 Next Generation Immunotherapy Market Size to Reach USD 5,545.0 Million by 2035, Impelled by Advancements in Biomarker-Driven Precision Medicine - BioSpace, accessed August 29, 2025, https://www.biospace.com/press-releases/lag-3-next-generation-immunotherapy-market-size-to-reach-usd-5-545-0-million-by-2035-impelled-by-advancements-in-biomarker-driven-precision-medicine
54. Nivolumab/relatlimab-rmbw (intravenous route) - Side effects & uses - Mayo Clinic, accessed August 29, 2025, https://www.mayoclinic.org/drugs-supplements/nivolumab-relatlimab-rmbw-intravenous-route/description/drg-20531825
55. Advanced Melanoma Treatment | Opdualag™ (nivolumab and ..., accessed August 29, 2025, https://www.opdualag.com/
56. Nivolumab Plus Relatlimab: First Approval - PubMed, accessed August 29, 2025, https://pubmed.ncbi.nlm.nih.gov/35543970/
57. Opdualag (Nivolumab + Relatlimab) Combination Treatment for Melanoma - MRA, accessed August 29, 2025, https://www.curemelanoma.org/patient-eng/melanoma-treatment/options/opdualag-nivolumab-relatlimab
58. Nivolumab/relatlimab - Wikipedia, accessed August 29, 2025, https://en.wikipedia.org/wiki/Nivolumab/relatlimab
59. Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy, accessed August 29, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1349081/full
60. Phase 3 Study of Novel Immunotherapy Combo Offers Promise in Advanced Melanoma, accessed August 29, 2025, https://www.targetedonc.com/view/phase-3-study-of-novel-immunotherapy-combo-offers-promise-in-advanced-melanoma
61. A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | ClinicalTrials.gov, accessed August 29, 2025, https://clinicaltrials.gov/ct2/show/NCT06246916?draw=2&rank=1
62. Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) - UC Clinical Trials, accessed August 29, 2025, https://clinicaltrials.ucbraid.org/trial/NCT06246916
63. Fianlimab | MedPath, accessed August 29, 2025, https://trial.medpath.com/drug/21397709d275c85c/fianlimab
64. Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO, accessed August 29, 2025, https://investor.regeneron.com/news-releases/news-release-details/regeneron-showcase-progress-innovative-oncology-portfolio/
65. Frequently Asked Questions: Breakthrough Therapies - FDA, accessed August 29, 2025, https://www.fda.gov/regulatory-information/food-and-drug-administration-safety-and-innovation-act-fdasia/frequently-asked-questions-breakthrough-therapies
66. Breakthrough Therapy Designation - Friends of Cancer Research, accessed August 29, 2025, https://friendsofcancerresearch.org/breakthrough-therapies/
67. Developing Standards for Breakthrough Therapy Designation in Oncology - PMC, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3745545/
68. Innate Pharma announces U.S. FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary Syndrome, accessed August 29, 2025, https://www.innate-pharma.com/media/all-press-releases/innate-pharma-announces-us-fda-granted-breakthrough-therapy-designation-lacutamab-relapsed-or-refractory-sezary-syndrome
69. Breakthrough Therapy - FDA, accessed August 29, 2025, https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy
70. Pfizer's Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma, accessed August 29, 2025, https://www.pfizer.com/news/press-release/press-release-detail/pfizers-elranatamab-granted-fda-breakthrough-therapy